Elicio Therapeutics, Inc.
ELTX
$10.60
-$0.43-3.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.24% | -31.51% | -47.46% | -42.39% | -31.36% |
| Total Depreciation and Amortization | 1.05% | -13.63% | 0.68% | -1.61% | -4.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,423.83% | 179.43% | 598.34% | 356.05% | -108.40% |
| Change in Net Operating Assets | 187.57% | 397.38% | 7,045.61% | -367.24% | 132.42% |
| Cash from Operations | 2.89% | 4.40% | -13.38% | -27.08% | -19.34% |
| Capital Expenditure | 48.28% | -77.55% | -31.82% | 73.91% | 25.00% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -91.18% | -91.18% | -91.18% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 46.43% | -625.00% | -162.50% | 69.29% | -2.44% |
| Total Debt Issued | -- | -- | 97.27% | 97.27% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 31.51% | 23.95% | 224.77% | 15,480.73% | 13,838.64% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27,550.00% | -102.54% | -102.54% | -102.53% | -99.99% |
| Cash from Financing | 189.34% | 5.12% | 9.60% | 14.74% | -64.27% |
| Foreign Exchange rate Adjustments | 530.77% | -- | -- | -- | -1,850.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 202.38% | 124.42% | -11.82% | -13.94% | -184.42% |